Skip to main content

Table 2 Clinical outcomes among US-enrolled induction therapy trial participants based on integrated trial records and OPTN follow-up data

From: Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants

  rATG % Basiliximab % P
Outcomes at 1 year    
 Acute rejection 14.3 % 22.8 % 0.08
 Patient survival 94.5 % 95.7 % 0.74
 All-cause graft survival 89.0 % 85.9 % 0.47
 Freedom from acute rejection, graft failure or death 80.0 % 68.5 % 0.04
 Any malignancy 1.1 % 1.1 % 0.99
 Post-transplant lymphoproliferative disorder 0 0 1.00
 Non-melanoma skin cancer 1.1 % 0 0.31
 Non-skin cancer 0 1.1 % 0.32
Outcomes at 5 years    
 Acute rejection 21.0 % 32.8 % 0.07
 Patient survival 72.5 % 75.0 % 0.64
 All-cause graft survival 67.5 % 60.6 % 0.32
 Freedom from acute rejection, graft failure, or death 57.6 % 44.2 % 0.04
 Any malignancy 4.5 % 4.5 % 0.97
 Post-transplant lymphoproliferative disorder 1.1 % 0 0.31
 Non-melanoma skin cancer 2.3 % 1.1 % 0.54
 Non-skin cancer 2.3 % 3.3 % 0.67
Outcomes at 10 years    
 Acute rejection 21.0 % 32.8 % 0.07
 Patient survival 52.8 % 52.2 % 0.92
 All-cause graft survival 34.3 % 30.9 % 0.56
 Freedom from acute rejection, graft failure, or death 32.6 % 24.0 % 0.09
 Any malignancy 9.5 % 8.1 % 0.75
 Post-transplant lymphoproliferative disorder 2.2 % 0 0.15
 Non-melanoma skin cancer 3.6 % 1.1 % 0.30
 Non-skin cancer 6.0 % 6.9 % 0.79